GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Cyclically Adjusted PS Ratio

Medigen Biotechnology (ROCO:3176) Cyclically Adjusted PS Ratio : 5.56 (As of Jun. 05, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Cyclically Adjusted PS Ratio?

As of today (2024-06-05), Medigen Biotechnology's current share price is NT$43.35. Medigen Biotechnology's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was NT$7.80. Medigen Biotechnology's Cyclically Adjusted PS Ratio for today is 5.56.

The historical rank and industry rank for Medigen Biotechnology's Cyclically Adjusted PS Ratio or its related term are showing as below:

ROCO:3176' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.36   Med: 18.73   Max: 40.16
Current: 5.52

During the past years, Medigen Biotechnology's highest Cyclically Adjusted PS Ratio was 40.16. The lowest was 4.36. And the median was 18.73.

ROCO:3176's Cyclically Adjusted PS Ratio is ranked worse than
50.2% of 504 companies
in the Biotechnology industry
Industry Median: 5.505 vs ROCO:3176: 5.52

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medigen Biotechnology's adjusted revenue per share data for the three months ended in Mar. 2024 was NT$1.806. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is NT$7.80 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Medigen Biotechnology Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Medigen Biotechnology's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Cyclically Adjusted PS Ratio Chart

Medigen Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.21 22.20 10.30 5.10 5.92

Medigen Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.79 4.74 4.61 5.92 4.97

Competitive Comparison of Medigen Biotechnology's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Medigen Biotechnology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Biotechnology's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's Cyclically Adjusted PS Ratio falls into.



Medigen Biotechnology Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Medigen Biotechnology's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=43.35/7.8
=5.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Medigen Biotechnology's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.806/131.7762*131.7762
=1.806

Current CPI (Mar. 2024) = 131.7762.

Medigen Biotechnology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.658 100.560 0.862
201409 0.691 100.428 0.907
201412 0.707 99.070 0.940
201503 0.546 99.621 0.722
201506 0.682 100.684 0.893
201509 0.691 100.392 0.907
201512 0.699 99.792 0.923
201603 0.754 100.470 0.989
201606 0.751 101.688 0.973
201609 0.718 101.861 0.929
201612 0.665 101.863 0.860
201703 0.732 102.862 0.938
201706 0.834 103.349 1.063
201709 0.758 104.136 0.959
201712 0.758 104.011 0.960
201803 0.791 105.290 0.990
201806 0.789 106.317 0.978
201809 0.716 106.507 0.886
201812 0.647 105.998 0.804
201903 0.766 107.251 0.941
201906 1.205 108.070 1.469
201909 0.802 108.329 0.976
201912 1.222 108.420 1.485
202003 0.943 108.902 1.141
202006 1.010 108.767 1.224
202009 1.101 109.815 1.321
202012 1.359 109.897 1.630
202103 1.334 111.754 1.573
202106 1.258 114.631 1.446
202109 10.016 115.734 11.404
202112 15.651 117.630 17.533
202203 3.485 121.301 3.786
202206 1.373 125.017 1.447
202209 1.272 125.227 1.339
202212 1.464 125.222 1.541
202303 1.180 127.348 1.221
202306 1.478 128.729 1.513
202309 3.009 129.860 3.053
202312 2.651 129.419 2.699
202403 1.806 131.776 1.806

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medigen Biotechnology  (ROCO:3176) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Medigen Biotechnology Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Biotechnology (ROCO:3176) Business Description

Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines